| ［1］ |
Xu J, Tahan S, Jan F, et al. Nail dystrophy as the initial sign of multiple myeloma⁃associated systemic amyloidosis［J］. J Cutan Pathol, 2016,43（6）:543⁃545. doi: 10.1111/cup.12675.
|
| ［2］ |
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis［J］. Lancet, 2016,387（10038）:2641⁃2654. doi: 10.1016/S0140⁃6736（15）01274⁃X.
|
| ［3］ |
Dinner S, Witteles W, Witteles R, et al. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis［J］. Br J Haematol, 2013,161（3）:367⁃372. doi: 10.1111/bjh.12269.
|
| ［4］ |
Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N⁃terminal pro⁃brain natriuretic peptide: a staging system for primary systemic amyloidosis［J］. J Clin Oncol, 2004,22（18）:3751⁃3757. doi: 10.1200/JCO.2004.03.029.
|
| ［5］ |
Nagano S, Mori M, Kato A, et al. Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma⁃associated AL amyloidosis［J］. Intern Med, 2013,52（10）:1101⁃1105. doi: 10.2169/ internalmedicine.52.8615.
|
| ［6］ |
Andrei M, Wang JC. Cutaneous light chain amyloidosis with multiple myeloma: a concise review［J］. Hematol Oncol Stem Cell Ther, 2019,12（2）:71⁃81. doi: 10.1016/j.hemonc.2018.09.003.
|
| ［7］ |
Huang X, Wang Q, Jiang S, et al. The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients［J］. Clin Kidney J, 2015,8（1）:120⁃126. doi: 10.1093/ckj/sfu117.
|
| ［8］ |
中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组. 原发性轻链型淀粉样变的诊断和治疗中国专家共识（2016年版）［J］. 中华血液学杂志, 2016,37（9）:742⁃746. doi: 10.3760/cma.j.issn.0253⁃2727.2016.09.003.
|
